Future Directions in Eosinophilic Esophagitis.

Ikuo Hirano

Journal: Gastrointestinal endoscopy clinics of North America 2018;28(1):111-122

PMID: 29129295

Full Text on Elsevier Science View on PubMed

Abstract

Eosinophilic esophagitis advances parallel the increased prevalence. Developments include refining the diagnostic criteria, identifying risk factors, appreciating the contribution of inflammatory pathways, recognizing the importance of subepithelial remodeling, validating trial endpoints, defining a role for biological therapies, and optimizing dietary therapy. Endoscopic outcomes have emerged as endpoints in trials of novel therapeutics. Expanding efforts seek to develop less-invasive methods to assess disease activity thereby reducing the burden of repeated endoscopic procedures during elimination diets. The functional lumen imaging probe is now identified as a determinant of complications with potential utility as a therapeutic endpoint.

Address: Division of Gastroenterology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair, Suite 1400, Chicago, IL 60611, USA.

DOI: 10.1016/j.giec.2017.07.010

Link outs

Free resources

Medical:

https://medlineplus.gov/eosinophilicesophagitis.ht...

Other Literature Sources:

https://scite.ai/reports/29129295

Subscription / membership required

Full Text Sources:

MeSH Terms: Biomarkers, Diet Therapy, Endpoint Determination, Eosinophilic Esophagitis, Esophagus, Humans, Phenotype, Risk Factors, Treatment Outcome